Adamis Pharmaceuticals Revenue and Competitors

Location

$67.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Adamis Pharmaceuticals's estimated annual revenue is currently $15M per year.(i)
  • Adamis Pharmaceuticals's estimated revenue per employee is $833,333
  • Adamis Pharmaceuticals's total funding is $67.5M.

Employee Data

  • Adamis Pharmaceuticals has 18 Employees.(i)
  • Adamis Pharmaceuticals grew their employee count by 0% last year.

Adamis Pharmaceuticals's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Accounting ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Adamis Pharmaceuticals?

Adamis Pharmaceuticals is a commercial-stage specialty pharmaceutical company targeting allergy, respiratory and pediatric medicine market segments through its Adamis Laboratories division. Adamis Labs is currently preparing for the commercial launch, via its existing sales force, of a pre-filled epinephrine syringe for use in the emergency treatment of extreme acute allergic reactions (anaphylaxis). Launch of this product is expected by mid 2009. Adamis Labs has two additional products in the pipeline: an inhaled nasal steroid for the treatment of allergic rhinitis and a metered dose inhaler for asthma and COPD, both projected to launch in 2011.

keywords:N/A

$67.5M

Total Funding

18

Number of Employees

$15M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Adamis Pharmaceuticals News

2022-03-30 - Adamis Pharmaceuticals Reports Full Year 2021 Financial ...

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in...

2022-03-22 - Adamis Pharmaceuticals Corporation Issues Nationwide ...

Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (Epinephrine) Injection for Potential Manufacturing Defect.

2022-03-22 - Adamis Pharmaceuticals Schedules Fourth Quarter and Full ...

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M18-18%N/A
#2
$2.8M186%N/A
#3
$2.4M18N/AN/A
#4
$1.6M18-5%N/A
#5
$1.8M18-5%N/A